Form 4: Aquestive Therapeutics Director Timothy Morris Granted 42,000 Stock Options

Aquestive Therapeutics, Inc. Director Timothy E. Morris was granted 42,000 stock options with an exercise price of $3.41, vesting fully on June 11, 2026.

Summary

• Timothy E. Morris, a Director of Aquestive Therapeutics, Inc. (AQST), was granted 42,000 stock options.
• The transaction date for this grant was June 11, 2025.
• The exercise price for these stock options is $3.41 per share.
• The options are scheduled to vest 100% on June 11, 2026, contingent upon Mr. Morris's continuous service with the Issuer from the grant date through the vesting date.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Mr. Morris beneficially owns 42,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation event, not indicative of major operational changes.

Positives

• The grant of stock options to Director Timothy E. Morris aligns his interests with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• This is a standard form of compensation for directors, indicating ongoing commitment and incentivization for long-term value creation.

Future Outlook

The vesting schedule of the stock options, with 100% vesting on June 11, 2026, indicates an expectation of Timothy E. Morris's continued service as a Director for at least one year from the grant date.

Industry Context

The granting of stock options to directors is a common practice in the pharmaceutical and biotechnology industries, serving as a key component of executive and director compensation packages to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation mechanism widely used across publicly traded companies, including those in the pharmaceutical sector like Aquestive Therapeutics.
• The vesting schedule (100% after one year) is a common approach for director equity grants, aiming to retain talent and incentivize long-term commitment, similar to practices observed at comparable companies such as BioDelivery Sciences International (BDSI) or Collegium Pharmaceutical (COLL) in their compensation structures for non-employee directors.

Related Party Transactions

• The transaction involves the grant of stock options to Timothy E. Morris, a Director of Aquestive Therapeutics, Inc., which is a standard compensation arrangement between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: The grant of options to a director can align management's incentives with shareholder interests, potentially leading to better long-term performance if the stock price increases.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The stock options will vest on June 11, 2026, provided Mr. Morris maintains continuous service with Aquestive Therapeutics, Inc.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Compensation, Corporate Governance